Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma

被引:1
|
作者
Glinka, Juan [1 ]
Diaz, Federico [2 ]
Alva, Augusto [2 ]
Mazza, Oscar [1 ]
Sanchez Claria, Rodrigo [1 ]
Ardiles, Victoria [1 ]
de Santibanes, Eduardo [1 ]
Pekolj, Juan [1 ]
de Santibanes, Martin [1 ]
机构
[1] Hosp Italiano Buenos Aires, Hepatobiliopancreat Unit, Dept Gen Surg, Buenos Aires, DF, Argentina
[2] Hosp Italiano Buenos Aires, Dept Radiat Oncol, Buenos Aires, DF, Argentina
来源
RADIATION ONCOLOGY JOURNAL | 2018年 / 36卷 / 03期
关键词
Pancreatic cancer; Radiotherapy; Chemoradiation;
D O I
10.3857/roj.2018.00206
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Pancreatic cancer (PC) has not changed overall survival in recent years despite therapeutic efforts. Surgery with curative intent has shown the best long-term oncological results. However, 80%-85% of patients with these tumors are unresectable at the time of diagnosis. In those patients, first therapeutic attempts are minimally invasive or surgical procedures to alleviate symptoms. The addition of radiotherapy (RT) to standard chemotherapy, ergo chemoradiation, in patients with locally advanced pancreatic cancer (LAPC) is still controversial. The study aims to compare outcomes in patients with a double bypass surgery due to LAPC treated or not with RT. Materials and Methods: A retrospective cohort study of patients with double bypass for LAPC were registered and divided into two groups: treated or not with postoperative RT. Baseline characteristics, postoperative complications, those related to RT and their relation to the main event (mortality) were compared. Results: Seventy-four patients were included. Surgical complications between the groups did not offer significant differences. Complications related to RT were mostly mild, and 86% of patients completed the treatment. Overall survival at 1 and 2 years for patients in the exposed group was 64% and 35% vs. 50% and 28% in the non-exposed group, respectively (p = 0.11; power 72%; hazard ratio = 0.53; 95% confidence interval, 0.24-1.18). Conclusion: We observed a tendency for survival improvement in patients with postoperative RT. However, we've not had enough power to demonstrate this difference, possibly due to the small sample size. It is indispensable to develop randomized and prospective trials to guide more specific treatment lines in this patients.
引用
收藏
页码:210 / 217
页数:8
相关论文
共 50 条
  • [31] Palliative Radiotherapy for Symptomatic Primary Tumors in Patients With Locally Advanced Breast Cancer
    Kim, Jae Sik
    Chang, Jee Suk
    Kim, Kyubo
    JOURNAL OF BREAST CANCER, 2024, 27 (04) : 223 - 234
  • [32] Management of unresectable, locally advanced pancreatic adenocarcinoma
    M. Salgado
    S. Arévalo
    O. Hernando
    A. Martínez
    R. Yaya
    M. Hidalgo
    Clinical and Translational Oncology, 2018, 20 : 113 - 118
  • [33] Genomic characterization of locally advanced pancreatic adenocarcinoma
    Picardo, Sarah L.
    O'Kane, Grainne
    Fischer, Sandra
    Zhang, Amy
    Denroche, Rob
    Jang, GunHo
    Dodd, Anna
    Grant, Robert
    Gruenwald, Barbara
    Moura, Shari
    Wang, Yifan
    Elimova, Elena
    Prince, Rebecca
    Zogopoulos, George
    Notta, Faiyaz
    Wilson, Julie
    Gallinger, Steve
    Knox, Jennifer
    CANCER RESEARCH, 2019, 79 (24)
  • [34] Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma
    Pollom, Erqi L.
    Koong, Albert C.
    Ko, Andrew H.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (04) : 741 - +
  • [35] GEMCITABINE PLUS RADIOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
    Otsuka, T.
    Kamachi, S.
    Akiyama, T.
    Fujimoto, M.
    Kawazoe, S.
    Ureshino, N.
    Watanabe, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 161 - 161
  • [36] Genomic characterisation of locally advanced pancreatic adenocarcinoma
    Picardo, S.
    O'Kane, G. M.
    Fischer, S.
    Zhang, A.
    Denroche, R.
    Jang, G.
    Dodd, A.
    Grant, R. C.
    Gruenwald, B.
    Moura, S.
    Wang, Y.
    Elimova, E.
    Prince, R.
    Zogopoulos, G.
    Notta, F.
    Wilson, J.
    Gallinger, S.
    Knox, J. J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Stereotactic radiotherapy after chemotherapy in patients with locally advanced pancreatic cancer
    LE ROY, C.
    Barbe, R.
    Sun, R.
    Burtin, P.
    Gelli, M.
    Deutsch, E.
    Durand-Labrunie, J.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1089 - S1089
  • [38] Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.
    de Lange, SM
    van Groeningen, CJ
    Giaccone, G
    Pinedo, HM
    Meijer, OWM
    Langendijk, JA
    Slotman, BJ
    CLINICAL CANCER RESEARCH, 2000, 6 : 4540S - 4541S
  • [39] Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer
    Hoeltgen, Line
    Meixner, Eva
    Hoegen, Philipp
    Sandrini, Elisabetta
    Weykamp, Fabian
    Forster, Tobias
    Vinsensia, Maria
    Lang, Kristin
    Koenig, Laila
    Arians, Nathalie
    Fremd, Carlo
    Michel, Laura L.
    Smetanay, Katharina
    Schneeweiss, Andreas
    Wallwiener, Markus
    Debus, Juergen
    Hoerner-Rieber, Juliane
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [40] Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer
    Hoeltgen, Line
    Meixner, Eva
    Hoegen, Philipp
    Sandrini, Elisabetta
    Weykamp, Fabian
    Forster, Tobias
    Vinsensia, Maria
    Lang, Kristin
    Koenig, Laila
    Arians, Nathalie
    Fremd, Carlo
    Michel, Laura L.
    Smetanay, Katharina
    Schneeweiss, Andreas
    Wallwiener, Markus
    Debus, Juergen
    Hoerner-Rieber, Juliane
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22